Hostname: page-component-586b7cd67f-g8jcs Total loading time: 0 Render date: 2024-11-22T10:57:17.224Z Has data issue: false hasContentIssue false
  • English
  • Français

The curious case of miR-155 in SLE

Published online by Cambridge University Press:  01 September 2021

S. A. Ibrahim ,
A. Y. Afify ,
I. O. Fawzy ,
N. El-Ekiaby  and
A. I. Abdelaziz Open the ORCID record for A. I. Abdelaziz [Opens in a new window]
S. A. Ibrahim
Affiliation:
School of Medicine, NewGiza University (NGU), Giza, Egypt
A. Y. Afify
Affiliation:
School of Medicine, NewGiza University (NGU), Giza, Egypt
I. O. Fawzy
Affiliation:
School of Medicine, NewGiza University (NGU), Giza, Egypt
N. El-Ekiaby
Affiliation:
School of Medicine, NewGiza University (NGU), Giza, Egypt
A. I. Abdelaziz*
Affiliation:
School of Medicine, NewGiza University (NGU), Giza, Egypt
*
Author for correspondence: A. I. Abdelaziz, E-mail: [email protected]
Get access Rights & Permissions [Opens in a new window]

Abstract

Epigenetic modifications have been well documented in autoimmune diseases. MicroRNAs (miRNAs), in particular, have long intrigued scientists in the field of autoimmunity. Owing to its central role in the development of the immune system, microRNA-155 (miR-155) is deeply involved in systemic lupus erythematosus (SLE). Despite the advancements made in treating SLE, the disease still remains incurable. Therefore, recent attention has been drawn to the manipulation of epigenetics in the development of curative treatments. In fact, it is a widely held view that miRNA-targeted therapy is a new glimmer of hope in the treatment of autoimmune diseases. However, the duplicity of miRNAs should not be overlooked. A single miRNA can target several mRNAs, and some mRNAs may possess opposing functions. In this review, we highlight the role of miR-155 as a biomarker and review its functions in SLE patients and animal models while discussing possible reasons behind inconsistencies across studies.

Keywords

SLEmiR-155epigenetics
Type
Review
Information
Expert Reviews in Molecular Medicine , Volume 23 , 2021 , e11
Copyright
Copyright © The Author(s), 2021. Published by Cambridge University Press

Access options

Get access to the full version of this content by using one of the access options below. (Log in options will check for institutional or personal access. Content may require purchase if you do not have access.)

References

Fava, A and Petri, M (2019) Systemic lupus erythematosus: diagnosis and clinical management. Journal of Autoimmunity 96, 1–13.CrossRefGoogle ScholarPubMed
Gottschalk, TA, Tsantikos, E and Hibbs, ML (2015) Pathogenic inflammation and Its therapeutic targeting in systemic lupus erythematosus. Frontiers in Immunology 6, 550.CrossRefGoogle ScholarPubMed
Rees, F et al. (2017) The worldwide incidence and prevalence of systemic lupus erythematosus: a systematic review of epidemiological studies. Rheumatology 56, 1945–1961.CrossRefGoogle ScholarPubMed
Hedrich, CM (2017) Epigenetics in SLE. Current Rheumatology Reports 19, 58.CrossRefGoogle ScholarPubMed
Friedman, RC et al. (2009) Most mammalian mRNAs are conserved targets of microRNAs. Genome Research 19, 92–105.CrossRefGoogle ScholarPubMed
Rodriguez, A et al. (2007) Requirement of bic/microRNA-155 for normal immune function. Science 316, 608–611.CrossRefGoogle ScholarPubMed
Mehta, A and Baltimore, D (2016) MicroRNAs as regulatory elements in immune system logic. Nature Reviews Immunology 16, 279–294.CrossRefGoogle ScholarPubMed
Su, LC et al. (2017) Role of microRNA-155 in rheumatoid arthritis. International Journal of Rheumatic Diseases 20, 1631–1637.CrossRefGoogle ScholarPubMed
Pisetsky, DS, Bossuyt, X and Meroni, PL (2019) ANA as an entry criterion for the classification of SLE. Autoimmunity Reviews 18, 102400. doi:10.1016/j.autrev.2019.102400CrossRefGoogle ScholarPubMed
Wen, Z et al. (2013) Autoantibody induction by DNA-containing immune complexes requires HMGB1 with the TLR2/microRNA-155 pathway. Journal of Immunology (Baltimore, MD: 1950) 190, 5411–5422.CrossRefGoogle ScholarPubMed
Ozaki, K et al. (2004) Regulation of B cell differentiation and plasma cell generation by IL-21, a novel inducer of blimp-1 and Bcl-6. Journal of Immunology (Baltimore, MD: 1950) 173, 5361–5371.CrossRefGoogle ScholarPubMed
Rasmussen, TK et al. (2015) Overexpression of microRNA-155 increases IL-21 mediated STAT3 signaling and IL-21 production in systemic lupus erythematosus. Arthritis Research & Therapy 17, 154. doi:10.1186/s13075-015-0660-zCrossRefGoogle ScholarPubMed
White, CA et al. (2014) Histone deacetylase inhibitors upregulate B cell microRNAs that silence AID and blimp-1 expression for epigenetic modulation of antibody and autoantibody responses. Journal of Immunology (Baltimore, MD: 1950) 193, 5933–5950.CrossRefGoogle ScholarPubMed
Chatzantoni, K and Mouzaki, A (2006) Anti-TNF-alpha antibody therapies in autoimmune diseases. Current Topics in Medicinal Chemistry 6, 1707–1714.CrossRefGoogle ScholarPubMed
Aringer, M and Smolen, JS (2003) SLE-complex cytokine effects in a complex autoimmune disease: tumor necrosis factor in systemic lupus erythematosus. Arthritis Research & Therapy 5, 172–177.CrossRefGoogle Scholar
Jacob, CO (1992) Tumor necrosis factor alpha in autoimmunity: pretty girl or old witch? Immunology Today 13, 122–125.CrossRefGoogle ScholarPubMed
Aboelenein, HR et al. (2017) Reduction of CD19 autoimmunity marker on B cells of paediatric SLE patients through repressing PU.1/TNF-alpha/BAFF axis pathway by miR-155. Growth Factors 35, 49–60.CrossRefGoogle Scholar
Gutierrez-Ramos, JC et al. (1991) Treatment with IL2/vaccinia recombinant virus leads to serologic, histologic and phenotypic normalization of autoimmune MRL/lpr-lpr mice. Autoimmunity 10, 15–25.CrossRefGoogle ScholarPubMed
Linker-Israeli, M et al. (1983) Defective production of interleukin 1 and interleukin 2 in patients with systemic lupus erythematosus (SLE). Journal of immunology (Baltimore, MD: 1950) 130, 2651–2655.Google Scholar
Melamed, A et al. (1988) The immune regulation in familial Mediterranean fever (FMF). Journal of Clinical & Laboratory Immunology 26, 125–128.Google Scholar
Lashine, YA et al. (2015) Correcting the expression of miRNA-155 represses PP2Ac and enhances the release of IL-2 in PBMCs of juvenile SLE patients. Lupus 24, 240–247.CrossRefGoogle ScholarPubMed
Lewis, EJ and Schwartz, MM (2005) Pathology of lupus nephritis. Lupus 14, 31–38.CrossRefGoogle ScholarPubMed
Dai, R and Ahmed, SA (2011) MicroRNA, a new paradigm for understanding immunoregulation, inflammation, and autoimmune diseases. Translational Research: The Journal of Laboratory and Clinical Medicine 157, 163–179.CrossRefGoogle Scholar
Kong, J et al. (2018) MicroRNA-155 suppresses mesangial cell proliferation and TGF-beta1 production via inhibiting CXCR5-ERK signaling pathway in lupus nephritis. Inflammation 42, 255–263. doi:10.1007/s10753-018-0889-1Google Scholar
Kaga, H et al. (2015) Downregulated expression of miR-155, miR-17, and miR-181b, and upregulated expression of activation-induced cytidine deaminase and interferon-alpha in PBMCs from patients with SLE. Modern Rheumatology 25, 865–870.CrossRefGoogle ScholarPubMed
Khoshmirsafa, M et al. (2018) Elevated expression of miR-21 and miR-155 in peripheral blood mononuclear cells as potential biomarkers for lupus nephritis. International Journal of Rheumatic Diseases 22, 458–467. doi: 10.1111/1756-185X.13410.CrossRefGoogle ScholarPubMed
Stagakis, E et al. (2011) Identification of novel microRNA signatures linked to human lupus disease activity and pathogenesis: miR-21 regulates aberrant T cell responses through regulation of PDCD4 expression. Annals of the Rheumatic Diseases 70, 1496–1506.CrossRefGoogle ScholarPubMed
Chauhan, SK et al. (2014) Differential microRNA profile and post-transcriptional regulation exist in systemic lupus erythematosus patients with distinct autoantibody specificities. Journal of Clinical Immunology 34, 491–503.CrossRefGoogle ScholarPubMed
Wang, H et al. (2012) Circulating microRNAs as candidate biomarkers in patients with systemic lupus erythematosus. Translational Research: The Journal of Laboratory and Clinical Medicine 160, 198–206.CrossRefGoogle ScholarPubMed
Carlsen, AL et al. (2013) Circulating microRNA expression profiles associated with systemic lupus erythematosus. Arthritis and Rheumatism 65, 1324–1334.CrossRefGoogle ScholarPubMed
Vahed, SZ et al. (2018) Altered levels of immune-regulatory microRNAs in plasma samples of patients with lupus nephritis. BioImpacts: BI 8, 177–183.CrossRefGoogle Scholar
Dai, ZW et al. (2018) Diagnostic accuracy of miRNAs as potential biomarkers for systemic lupus erythematosus: a meta-analysis. Clinical Rheumatology 37, 2999–3007.CrossRefGoogle ScholarPubMed
Wang, G et al. (2010) Serum and urinary cell-free MiR-146a and MiR-155 in patients with systemic lupus erythematosus. The Journal of Rheumatology 37, 2516–2522.CrossRefGoogle ScholarPubMed
Abulaban, KM et al. (2016) Relationship of cell-free urine MicroRNA with lupus nephritis in children. Pediatric Rheumatology Online Journal 14, 4.CrossRefGoogle ScholarPubMed
Wang, G et al. (2012) Expression of miR-146a and miR-155 in the urinary sediment of systemic lupus erythematosus. Clinical Rheumatology 31, 435–440.CrossRefGoogle ScholarPubMed
Richard, ML and Gilkeson, G (2018) Mouse models of lupus: what they tell us and what they don't. Lupus Science & Medicine 5, e000199.CrossRefGoogle ScholarPubMed
Dai, R et al. (2010) Identification of a common lupus disease-associated microRNA expression pattern in three different murine models of lupus. PLoS ONE 5, e14302.CrossRefGoogle ScholarPubMed
Zarate-Neira, LA et al. (2017) Dysregulation of miR-155-5p and miR-200-3p and the anti-non-bilayer phospholipid arrangement antibodies favor the development of lupus in three novel murine lupus models. Journal of Immunology Research 2017, 8751642.CrossRefGoogle ScholarPubMed
Thai, TH et al. (2013) Deletion of microRNA-155 reduces autoantibody responses and alleviates lupus-like disease in the Fas(lpr) mouse. Proceedings of the National Academy of Sciences of the United States of America 110, 20194–9.CrossRefGoogle ScholarPubMed
Xin, Q et al. (2015) miR-155 deficiency ameliorates autoimmune inflammation of systemic lupus erythematosus by targeting S1pr1 in Faslpr/lpr mice. Journal of immunology (Baltimore, MD: 1950) 194, 5437–5445.CrossRefGoogle ScholarPubMed
Leiss, H et al. (2017) MicroRNA 155-deficiency leads to decreased autoantibody levels and reduced severity of nephritis and pneumonitis in pristane-induced lupus. PLoS ONE 12, e0181015.CrossRefGoogle ScholarPubMed
Zhou, S et al. (2016) In vivo therapeutic success of microRNA-155 antagomir in a mouse model of lupus alveolar hemorrhage. Arthritis & Rheumatology 68, 953–964.CrossRefGoogle Scholar
Liu, F et al. (2015) TLR9-induced miR-155 and Ets-1 decrease expression of CD1d on B cells in SLE. European Journal of Immunology 45, 1934–1945.CrossRefGoogle Scholar
Divekar, AA et al. (2011) Dicer insufficiency and microRNA-155 overexpression in lupus regulatory T cells: an apparent paradox in the setting of an inflammatory milieu. Journal of Immunology (Baltimore, MD: 1950) 186:924–930.CrossRefGoogle ScholarPubMed
Cifuentes, D et al. (2010) A novel miRNA processing pathway independent of dicer requires Argonaute2 catalytic activity. Science 328, 1694–1698.CrossRefGoogle ScholarPubMed
Choi, SC et al. (2016) The lupus susceptibility gene Pbx1 regulates the balance between follicular helper T cell and regulatory T cell differentiation. Journal of Immunology (Baltimore, MD: 1950) 197, 458–469.CrossRefGoogle ScholarPubMed
Svoronos, AA, Engelman, DM and Slack, FJ (2016) OncomiR or tumor suppressor? The duplicity of microRNAs in cancer. Cancer Research 76, 3666–3670.CrossRefGoogle ScholarPubMed
Zan, H and Casali, P (2013) Regulation of aicda expression and AID activity. Autoimmunity 46, 83–101.CrossRefGoogle ScholarPubMed
Shumnalieva, R et al. (2018) Whole peripheral blood miR-146a and miR-155 expression levels in systemic lupus erythematosus patients. Acta Reumatologica Portuguesa 43, 217–225.Google ScholarPubMed
Chung, JW et al. (2017) Expression of microRNA in host cells infected with Helicobacter pylori. Gut and Liver 11, 392–400.CrossRefGoogle ScholarPubMed
Palmer, JD et al. (2014) MicroRNA expression altered by diet: can food be medicinal? Ageing Research Reviews 17, 16–24.CrossRefGoogle ScholarPubMed
Cortes-Marquez, AC et al. (2018) Differential expression of miRNA-146a and miRNA-155 in gastritis induced by Helicobacter pylori infection in paediatric patients, adults, and an animal model. BMC Infectious Diseases 18, 463.CrossRefGoogle ScholarPubMed
Shah, N and Singh, I (2017) MicroRNA profiling identifies miR-196a as differentially expressed in childhood adrenoleukodystrophy and adult adrenomyeloneuropathy. Molecular Neurobiology 54, 1392–1403.CrossRefGoogle ScholarPubMed
Chafin, CB et al. (2013) Cellular and urinary microRNA alterations in NZB/W mice with hydroxychloroquine or prednisone treatment. International Immunopharmacology 17, 894–906.CrossRefGoogle ScholarPubMed